Advertisement

Topics

Celgene Oncology Exec Pehl Named Immunomedics President and CEO

10:16 EST 17 Nov 2017 | Xconomy

Michael Pehl has been appointed president and CEO of cancer drug developer Immunomedics (NASDAQ: IMMU). Pehl comes to the Morris Plains, NJ, company from Celgene (NASDAQ: CELG), where he was president, hematology & oncology. He will start his new position at Immunomedics on Dec. 7. Immunomedics is moving forward with sacituzumab govitecan, a breast cancer […]

Original Article: Celgene Oncology Exec Pehl Named Immunomedics President and CEO

NEXT ARTICLE

More From BioPortfolio on "Celgene Oncology Exec Pehl Named Immunomedics President and CEO"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Diagnostics
A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example: to diagnose diseases to measure the progress or recovery from disease to confirm that a person is free from disease Clin...